Sana Biotechnology
Clinical trials sponsored by Sana Biotechnology, explained in plain language.
A biotechnology company developing engineered cell therapies for various diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Experimental donor immune cells target Hard-to-Treat lymphoma
Disease control OngoingThis early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check …
Phase 1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Experimental Donor-Cell therapy takes aim at tough autoimmune diseases
Disease control OngoingThis early-stage study tests a therapy called SC291, made from donor immune cells, in 7 people with severe lupus or vasculitis that hasn't improved with standard treatments. The goal is to see if it is safe and tolerable, and to get a first look at whether it can control the dise…
Phase 1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Engineered donor cells take on tough lymphomas and leukemias
Disease control OngoingThis early-phase study tests SC291, a CAR T-cell therapy made from donor cells, in 16 adults with relapsed or refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia. The goal is to check safety and see if the treatment can shrink tumors. Because it uses donor cell…
Phase 1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC